Evidence map›Paper›PMID 40128996›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Hepatocellular Carcinoma Arising Adjacent to Antiphospholipid Syndrome-associated Hepatic Infarction in a Non-cirrhotic Liver.

Yuriko Kusumi, Takumu Hasebe, Manami Hayashi, Yuki Kamikokura, Shin Otake, Hidemi Hayashi, Yu Ota, Shunsuke Nakajima, Kazunobu Aso, Koji Sawada and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuriko KusumiDepartment of Internal Medicine, Division of Gastroenterology, Asahikawa Medical University, Japan.
Takumu HasebeDepartment of Internal Medicine, Division of Gastroenterology, Asahikawa Medical University, Japan.
Manami HayashiDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Japan.
Yuki KamikokuraDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Japan.
Shin OtakeDepartment of Internal Medicine, Division of Gastroenterology, Asahikawa Medical University, Japan.
Hidemi HayashiDepartment of Community Medicine Management, Asahikawa Medical University, Japan.
Yu OtaDepartment of Internal Medicine, Division of Gastroenterology, Asahikawa Medical University, Japan.
Shunsuke NakajimaDepartment of Internal Medicine, Division of Gastroenterology, Asahikawa Medical University, Japan.
Kazunobu AsoDepartment of Internal Medicine, Division of Gastroenterology, Asahikawa Medical University, Japan.
Koji SawadaDepartment of Internal Medicine, Division of Gastroenterology, Asahikawa Medical University, Japan.
Mishie TaninoDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Japan.
Mikihiro FujiyaDepartment of Internal Medicine, Division of Gastroenterology, Asahikawa Medical University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A man in his 70s with antiphospholipid syndrome (APS) presented with a hepatic mass. Initial imaging suggested hepatic infarction, as the liver tumor markers were normal, and coagulation tests indicated a hypercoagulable state. Three years later, follow-up imaging revealed tumor enlargement, leading to a biopsy-confirmed hepatocellular carcinoma diagnosis. Transarterial embolization was performed followed by lenvatinib therapy. The patient achieved complete response with no recurrence for over eight months. This case highlights the potential of APS to contribute to liver carcinogenesis in non-cirrhotic patients and illustrates the need for individualized treatment strategies.

Indexed as

Antiphospholipid SyndromeCarcinoma, HepatocellularInfarctionLiverLiver NeoplasmsAgedHumansMalePhenylurea CompoundsQuinolineslenvatinibPhenylurea CompoundsQuinolinesantiphospholipid syndromehepatic infarctionhepatocellular carcinomalenvatinibnon-cirrhotic livertransarterial embolization

Identifiers

PMID40128996
PMCPMC12549042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.